

2025.01.13



PRESS RELEASE

Cell4Cure to exhibit at Arab Health Exhibition and Congress 2025

Solna, Sweden, 13 January 2025, Cell4Cure AB – a Swedish, privately held biotech company, founded in 2023, pioneering immune tolerance therapies – today announced that they will participate at Arab Health Exhibition and Congress taking place in Dubai 27-30 January.

Arab Health is the premier platform that unites the global healthcare professionals. As the largest gathering of healthcare professionals and industry experts in the Middle East, it offers a unique opportunity to explore the latest trends, advancements and innovations in the field.

"This meeting provides a good opportunity for us to update investors and partners of our ongoing plans and triggers, and specifically look for investors and partners for our development of novel therapies for anti-drug antibody (ADA) eradication" says CEO, Christina Herder.

Christina Herder, CEO
Telephone: +46 703747156
E-mail: christina.herder@cell4cure.com

About Cell4Cure

Cell4Cure AB, a Swedish, privately held biotech company, founded in 2023, is pioneering immune tolerance therapies aimed at addressing significant clinical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejections. The company's proprietary platform leverages ex vivo-generated dendritic cells (DCs) engineered to induce antigen-specific tolerance.

These tolerogenic DCs offer a targeted approach to mitigating unwanted immune responses while preserving essential immune functions.

Based on \$30 million in R&D investments, the technology platform has reached key development milestones, i.e. EMA approval for clinical trials, and the establishment of robust GMP manufacturing processes.

For more information visit www.cell4cure.com.